Soligenix to Showcase Major Developments at BIO Investment Summit in Miami

Soligenix to Present at BIO Investment & Growth Summit

Soligenix, Inc. (Nasdaq: SNGX), a leader in the biopharmaceutical sector specializing in treatments for rare diseases, has announced its participation at the upcoming BIO Investment & Growth Summit. Scheduled for March 2-3, 2026, this event will be held at the Eden Roc Miami Beach hotel in Miami, Florida. Christopher J. Schaber, Ph.D., the President and CEO of Soligenix, is set to deliver a corporate presentation at 3:00 PM on the first day of the conference.

The BIO Investment & Growth Summit represents a key opportunity for investment and networking, bringing together innovative programs, one-on-one meetings, and insights from various companies in the biotechnology field. Attendees of the conference will have the chance to engage with Soligenix through scheduled meetings, providing a platform for potential investors to gain deeper insights into the company's advancements and goals in treating conditions with significant unmet medical needs.

About Soligenix

Soligenix operates primarily in two business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment focuses on advancing therapies for rare diseases, with a notable highlight being the potential commercialization of HyBryte™ (SGX301). HyBryte™ is a groundbreaking photodynamic therapy that employs visible light for treating cutaneous T-cell lymphoma (CTCL). Following the successful completion of the second Phase 3 study, the company intends to seek regulatory approvals to facilitate global commercialization of this promising treatment.

In addition to HyBryte™, the company’s pipeline includes SGX302, aimed at treating psoriasis, and SGX942, designed to address inflammatory diseases such as oral mucositis associated with head and neck cancer. Furthermore, SGX945 targets Behçet's Disease, showcasing Soligenix's commitment to innovative and effective treatments.

The Public Health Solutions segment of Soligenix is equally vital, focusing on developing critical vaccines and therapeutics. Key projects include RiVax®, a candidate vaccine to protect against ricin toxin, and vaccine programs targeting severe viruses like Marburg and Ebola. Additionally, CiVax™, which is designed to prevent COVID-19, exhibits the company’s diversification into prominent public health challenges. Their proprietary heat stabilization platform, ThermoVax®, underpins these vaccine development programs, substantially enhancing their viability in varying conditions.

The progress and potential of Soligenix’s products are underpinned by substantial funding and support from government agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). These collaborations not only strengthen their products' development journey but also highlight the importance placed on national health security.

As Soligenix approaches this pivotal presentation at the BIO Summit, stakeholders and investors are keenly anticipating insights into their strategic advancements and future milestones. This update is expected to include reflections on their recent clinical trial outcomes and outlines on how emerging therapies align with the company's roadmap towards commercialization.

Concluding Thoughts

Participation at such a prestigious event underscores Soligenix's commitment to advancing biopharmaceutical innovation. By showcasing their developments, they aim to attract investments that can further enhance their capabilities in commercializing essential treatments for rare diseases and public health threats. The BIO Investment & Growth Summit is not just an opportunity for Soligenix to present but a critical juncture for fostering partnerships that could shape the future landscape of healthcare.

For more details about Soligenix and its innovative products, visit the company’s website and follow them on LinkedIn and Twitter @Soligenix_Inc.